Ontology highlight
ABSTRACT:
SUBMITTER: Cheson BD
PROVIDER: S-EPMC4840280 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Cheson Bruce D BD Brugger Wolfram W Damaj Gandhi G Dreyling Martin M Kahl Brad B Kimby Eva E Ogura Michinori M Weidmann Eckhart E Wendtner Clemens-Martin CM Zinzani Pier Luigi PL
Leukemia & lymphoma 20151123 4
Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel o ...[more]